CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 8 enrolled
Drug / intervention
Autologous Tumor Infiltrating Lymphocytes +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04812470
NCT04812470Phase 1Completed
CompareCT.gov

A Phase I Study Using Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases

Vastra Gotaland Region·interventional·Posted Mar 23, 2021·Updated Sep 22, 2025

In Brief

A Phase 1 clinical trial evaluating Autologous Tumor Infiltrating Lymphocytes, Melphalan, and 1 other intervention for Metastatic Uveal Melanoma and Metastatic Cutaneous Melanoma. Completed, enrolled 8 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the feasibility, safety and tolerability of treatment with autologous tumor infiltrating lymphocytes (TIL) administered via hepatic arterial infusion in patients with liver metastases (including but not restricted to) of malignant melanoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Uveal Melanoma, Metastatic Cutaneous Melanoma
CountriesSweden
CollaboratorsMiltenyi Biomedicine GmbH

Timeline

Phase 1CompletedFinished
20222023202420252026
First PostedMar 23, 2021
Enrollment StartFeb 6, 2023
Primary CompletionMay 26, 2025
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 5.3 years ago

Interventions

Autologous Tumor Infiltrating Lymphocytesdrug

Administered via hepatic arterial infusion

Melphalandrug

Melphalan will be administered once as an intravenous infusion.

Interleukin-2drug

After TIL infusion, Interleukin-2 will be administered subcutaneously once daily for up to 14 days.